Class Action Lawsuit Filed Against Replimune Group, Inc.
A class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) by Pomerantz LLP due to alleged securities fraud or other unlawful business practices involving the company and its officers or directors. Investors who purchased shares during a specified period are encouraged to contact the firm for more information. The legal action follows an April 10, 2026 FDA Complete Response Letter rejecting Replimune's Biologics License Application (BLA) for RP1 in combination with nivolumab. The FDA cited deficiencies in clinical trials and noted that evidence did not meet regulatory standards. This led to a significant drop in the company’s stock price, falling 19.46% on April 10 and an additional 64.29% by April 13. Replimune's press release following the FDA decision acknowledged concerns about trial design but claimed that single-arm trials could be acceptable under certain conditions for accelerated approval.
Tickers: $REPL
Topics: biologics license application class action lawsuit fda rejection securities fraud